Stephen Nava
Corporate Officer/Principal bei Regulator Affairs Quality Assurance Consulting Services, Inc.
Profil
Stephen Nava is the owner of Regulator Affairs Quality Assurance Consulting Services, Inc. since 2004.
He was the Director of Regulatory Affairs & Quality Assurance at BiPar Sciences, Inc. from 2005 to 2011 and the Director of Regulatory Affairs at Acumen Sciences LLC from 2002 to 2004.
He also held the position of Vice President of Compliance & Regulatory Affairs at Sunesis Pharmaceuticals, Inc. Mr. Nava received his undergraduate degree from Texas A&M University-Kingsville.
Aktive Positionen von Stephen Nava
| Unternehmen | Position | Beginn |
|---|---|---|
| Regulator Affairs Quality Assurance Consulting Services, Inc. | Corporate Officer/Principal | 01.01.2004 |
Ehemalige bekannte Positionen von Stephen Nava
| Unternehmen | Position | Ende |
|---|---|---|
BiPar Sciences, Inc.
 BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | General Counsel | 01.06.2011 |
| Acumen Sciences LLC | General Counsel | 01.01.2004 |
| VIRACTA THERAPEUTICS, INC. | Compliance Officer | - |
Ausbildung von Stephen Nava
| Texas A&M University-Kingsville | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
BiPar Sciences, Inc.
BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Health Technology |
| Acumen Sciences LLC | |
| Regulator Affairs Quality Assurance Consulting Services, Inc. |
